Skip to main content
Is IL-23i better than IL-17i at lowering PsA risk? Retrospective, real-world EHR data study from TriNetX shows that amon

Dr. John Cush RheumNow

1 year 6 months ago
Is IL-23i better than IL-17i at lowering PsA risk? Retrospective, real-world EHR data study from TriNetX shows that among 4580 adult psoriasis pts (2,273 on IL23i vs 2,307 on IL17i), IL23i had signif lower PsA incidence (HR 0.60; 0.44–0.82, P 0.001), esp if 41-65 yrs (HR 0.42) &… https://t.co/ZuCAiOTIke https://t.co/8PkDCugYy0
QD Clinic - dsDNA without Lupus

Insufficient Sxs to Dx SLE, but persistent dsDNA positivity - what to do?

Features D

Dr. John Cush RheumNow

1 year 6 months ago
QD Clinic - dsDNA without Lupus Insufficient Sxs to Dx SLE, but persistent dsDNA positivity - what to do? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6https://t.co/ov8THqrPyC https://t.co/jmtqxcWzJ0
QD Clinic - New Palmoplantar Psoriasis and PsA

New Onset Palmoplantar PsO and PsA - what are the options?

Features D

Dr. John Cush RheumNow

1 year 6 months ago
QD Clinic - New Palmoplantar Psoriasis and PsA New Onset Palmoplantar PsO and PsA - what are the options? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6https://t.co/HZZuDvga58 https://t.co/wWKhnIECwB
The American College of Rheumatology (ACR) applauded the bipartisan introduction of the Medicare Patient Access and Practice Stabilization Act of 2025, legislation to fully offset the harmful 2.8% cut in the Medicare Physician Fee Schedule (MPFS). The bill, led by Representatives Greg Murphy, MD (R-NC) and Jimmy Panetta (D-CA), includes an additional 2% payment update to physician services furnished after April 1 of this year.
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.
Blood Flow Restriction to Reduce Pain in Knee OA

A technique now widely used in sports medicine to speed recovery from

Dr. John Cush RheumNow

1 year 6 months ago
Blood Flow Restriction to Reduce Pain in Knee OA A technique now widely used in sports medicine to speed recovery from leg injuries helped reduce symptoms and improve function in people with osteoarthritis (OA) of the knee, a randomized trial showed. https://t.co/IF1tkT5yvC https://t.co/0zQn8oBjeG
Dannish study of 1 million infants, exposed vs unexposed to systemic glucocorticoids shows prenatal GC exposure assoc w/

Dr. John Cush RheumNow

1 year 6 months ago
Dannish study of 1 million infants, exposed vs unexposed to systemic glucocorticoids shows prenatal GC exposure assoc w/ higher risk of autism (RR 1.5), intellectual disability (1.3), ADHD (1.3), mood/anxiety (1.3). Same risk for 290K mothers w/ autoimmune/inflamm Dz… https://t.co/bXL3YqCIYZ https://t.co/psNVENXRPs
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/

Dr. John Cush RheumNow

1 year 6 months ago
SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/zvYGct9aqG https://t.co/obgkHbXNWA
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned la

Dr. John Cush RheumNow

1 year 6 months ago
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/xUPXA79weS https://t.co/eUeemqovv8
Seats are still available for virtual attendees! Join us THIS WEEKEND for RheumNow Live!

https://t.co/kSd7tKywmM https

Dr. John Cush RheumNow

1 year 6 months ago
Seats are still available for virtual attendees! Join us THIS WEEKEND for RheumNow Live! https://t.co/kSd7tKywmM https://t.co/oyyY5EK04m
Participation is Up! (1.31.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. We

Dr. John Cush RheumNow

1 year 6 months ago
Participation is Up! (1.31.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. We also have two call-in cases on "Ask Cush Anything". https://t.co/kxMkDW5X8c https://t.co/AjIuNzk7co
How did Rheumatology go from being the happiest specialist to now being 5th from the bottom at 65%? Top heavy happiness

Dr. John Cush RheumNow

1 year 6 months ago
How did Rheumatology go from being the happiest specialist to now being 5th from the bottom at 65%? Top heavy happiness seems to be influenced by income? what do you think? Allergy 94% Pathology 88% Dermatology 87% .... Rheum 67% Internal med 66%... https://t.co/YTKMElL868 https://t.co/RnsIVYWBFo
Target Trial Emulation Study from EUSTAR - Adding po glucocorticoids (<20mg/d Pred) to immunosuppressives to 208 earl

Dr. John Cush RheumNow

1 year 6 months ago
Target Trial Emulation Study from EUSTAR - Adding po glucocorticoids (<20mg/d Pred) to immunosuppressives to 208 early diffuse systemic sclerosis pts does not improve skin scores. 12 mos mRSS change similar (-2.7 vs -3.1); same w/ shorter dz (≤ 24 mos) or w/ mRSS ≤22.… https://t.co/QVbhFOEfIk https://t.co/9GrRpaWenh
A 3rd Actemra biosimilar was approved by the FDA - Celltrion announced approval of its 7th biosimilar, Avtozma (CT-P47,

Dr. John Cush RheumNow

1 year 6 months ago
A 3rd Actemra biosimilar was approved by the FDA - Celltrion announced approval of its 7th biosimilar, Avtozma (CT-P47, tocilizumab-anoh); both IV & SCm for Rx of RA, GCA, pJIA, Still's dz & Covid-19. Joins other IL-6 biosimilars Tofidence (Biogen 10/23) & Tyenne (Frensius 3/24)… https://t.co/UtG9YOXUX2 https://t.co/j3LzG7beys
×